How to Capitalize on Germany’s Move to Legalize Cannabis
Ryan Allway
November 30th, 2021
App, Exclusive, News, Top News
Germany’s incoming governing parties recently announced a formal agreement to legalize adult-use cannabis when they take power. While personal possession has already been decriminalized, the new proposal seeks to establish a regulated market for adult-use cannabis. The move could create an industry like those in Canada and some U.S. states.
While the legislation won’t be finalized for at least a year, cannabis imports are likely to play a critical role in the local market given the lack of domestic cultivation. As a result, there’s a significant opportunity for companies that export products to the newly legal market, including both domestic and international cultivators and manufacturers.
Let’s look at how Flora Growth Corp. (NASDAQ: FLGC) is positioning itself to capitalize on Germany’s upcoming recreational cannabis market and why investors should take a closer look at the stock over the coming quarters.
Unique Partnership
Flora Growth previously announced a €2 million investment and strategic partnership with Hoshi International Inc., a medical cannabis business with a growing European presence. With operations being built out to span cultivation, manufacturing, and distribution, the company is uniquely positioned to become a leading European cannabis supplier.
Through the partnership, Flora intends to cultivate product in Colombia and send it to Malta, where Hoshi could process it into E.U. GMP product that’s free to move into Germany and other European markets. With its premium and low-cost cultivation, Flora could offer a significant competitive advantage over other global cannabis suppliers.
Click here to receive an investor presentation and corporate updates
Luxembourg, Italy, France, Switzerland, and Malta have all introduced measures to decriminalize or legalize some form of cannabis within their borders. For example, Switzerland began a pilot program for adult-use cannabis and France began a medical cannabis test program in a bid to become the 23rd European country that permits medical cannabis use.
Low-Cost Production
Flora Growth leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, spanning cosmetics, hemp textiles, and food and beverage. In addition, the company operates one of the largest outdoor cultivation facilities in the world, Cosechemos, enabling it to cultivate and process premium product at below market prices.
The company has demonstrated that it can achieve a production cost of less than six cents per gram of dried flower. These prices yield attractive profit margins and below-market prices, making it easy to dominate new markets—particularly in high cost regions of the world.
For example, if the company were to sell at $1.00 per gram, it would realize an 80% profit margin while putting most Canadian producers into the red. The company is also already harvesting non-psychoactive CBD cultivars with yields that are 40% to 60% higher than management originally anticipated with high-THC cultivars coming this month.
Bullish Analyst Outlook
The German market offers a compelling opportunity for future growth, but Flora Growth is already generating revenue in the interim. The company’s branded beauty products account for the lion’s share of sales, but dried CBD flower provides further upside potential, setting the stage for an annual run rate of more than $40 million by some estimates.
The company reported revenue of $2 million with a 60% gross margin during the first half of 2021, but management expects revenue of $9 million to $11 million, exclusively of M&A and dried flower shipments, during the second half of the year.
MKM Partners believes that net sales could reach nearly $70 million in 2023 with adjusted EBITDA of $25 million and strong double-digit growth through 2028. As a result, the analyst issued a Buy rating and a $11.50 per share price target, reflecting a significant premium over the current market price of just $2.11 per share.
Looking Ahead
Germany’s move to legalize and regulate recreational cannabis could be the first domino to fall and lead to a wave of legalizations across the European market. Flora Growth Corp. (NASDAQ: FLGC) is well-positioned to benefit from the move through its partnership with Hoshi International Inc., a leading cultivator, manufacturer, and distributor in the European market.
In the meantime, the company is already generating substantial revenue through the sale of beauty, hemp textiles, and food and beverage products, and soon bulk CBD flower. These products generated $2 million in sales during the first half of the year and could accelerate to upwards of $10 million over the second half of the year.
Investors may want to keep an eye on the stock over the coming quarters given these catalysts.
Click here to receive an investor presentation and corporate updates
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
MediPharm is a pioneer in the cannabis industry as it is the first company in Canada to successfully become a Licensed Producer for cannabis oil production without first receiving a cannabis cultivation license.
DNA Genetics has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
